Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 8/20 | 0.58 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA7 | P43166 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23114207 | 0.89 | CYP2A6 (0.79) | CYP2A6MCL1CA9CA12CA1 | |
| SCHEMBL15842328 | 0.82 | CYP2A6 (0.70) | CYP2A6MCL1CA9CA12CA1 | |
| SCHEMBL16283614 | 0.81 | CYP2A6 (0.68) | CYP2A6MCL1CA9CA12CA1 | |
| SCHEMBL11033454 | 0.81 | CYP2A6 (0.68) | CYP2A6CA9CA12CA1CA7 | |
| SCHEMBL15842762 | 0.81 | CYP2A6 (0.68) | CYP2A6MCL1CA9CA12CA1 | |
| SCHEMBL16283609 | 0.80 | CYP2A6 (0.66) | CYP2A6MCL1CA9CA12KDM4E | |
| SCHEMBL3362753 | 0.78 | CA9 (0.70) | CYP2A6MCL1CA9CA12CA1 | |
| SCHEMBL4181037 | 0.78 | MCL1 (0.67) | CYP2A6MCL1CA9CA12CA1 | |
| SCHEMBL15842592 | 0.77 | CYP2A6 (0.63) | CYP2A6MCL1CA9CA12CA1 | |
| SCHEMBL15842313 | 0.77 | CYP2A6 (0.62) | CYP2A6MCL1CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110283180-B | Method for synthesizing pyridine [3,4-c ] coumarin | 长沙理工大学 | 2022-03-29 | — | — | CN | claimed |
| US-9127092-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | claimed |
| US-20140187725-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2014-07-03 | — | — | US | claimed |
| CN-110283180-B | Method for synthesizing pyridine [3,4-c ] coumarin | 长沙理工大学 | 2022-03-29 | — | — | CN | disclosed |
| US-10633369-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2020-04-28 | — | — | US | disclosed |
| CN-110317226-A | Silane coupling compound and medical courses in general curable composition for dental applications containing them | 株式会社松风 | 2019-10-11 | — | — | CN | disclosed |
| CN-106674175-B | The synthetic method of coumarin kind compound | 西交利物浦大学 | 2019-03-26 | — | — | CN | disclosed |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | 4 SC AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9951050-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-2813891-B1 | Photoresist underlayer film-forming composition and pattern forming process | SHINETSU CHEMICAL CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-0942911-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | Abbott Laboratories (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5891882-A | TREATING BENIGN PROSTATIC HYPERPLASIA OR OTHER UROLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION AND NEUROGENIC BLADDER, OR GYNECOLOGICAL SYNDROMES SUCH AS DYSMENORRHEA | ABBOTT LABORATORIES (US) | 1999-04-06 | — | — | US | disclosed |
| US-5808105-A | 4-phenoxycoumarins as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1998024791-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5759959-A | SELECTIVE CONTROL OF MONOCOTYLEDENOUS WEEDS IN THE PRESENCE OF A CROP PLANT | AMERICAN CYANAMID COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5681968-A | EFFECTIVE TO CONTROL GRASS AND OTHER MONOCOTOLYDENOUS WEEDS | AMERICAN CYANAMID COMPANY (US) | 1997-10-28 | — | — | US | disclosed |
| US-5563280-A | CONTROLLING MONOCOTYLEDENOUS WEEDS IN CROPS | AMERICAN CYANAMID CO. (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0694257-A1 | 4-Phenoxycoumarins and thio derivatives thereof, their preparation and use as herbicides | AMERICAN CYANAMID COMPANY (US) | 1996-01-31 | — | — | EP | disclosed |
| US-4441969-A | ARYL HYDROXY CARBOXYLIC ACID | OMI INTERNATIONAL CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633369-B2 | Method of inhibiting DYRK1B | SMO, GLI1, GRK2 | CYP2A6 4696/4885MCL1 748/4885CA9 2105/4885 |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | CYP2A6 4696/4885MCL1 748/4885CA9 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.